1.	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446GUS45, ZENITH, NCT00063609
2.	A Multiple Myeloma Trial in Patients With Bone Metastases Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EUS97, US97, NCT00104104
3.	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Phase: Phase IV Type: Supportive care Status: Completed Age: 18 to 120 Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EIT04, NCT00219219
4.	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Phase: Phase IV Type: Treatment Status: Completed Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446GGR01, NCT00219271
5.	Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EDE06, NCT00171964
6.	Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EDE15, NCT00172003
7.	A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss Phase: Phase IV Type: Biomarker/Laboratory analysis, Supportive care Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446GDE13, 2004-002831-14, NCT00333229
8.	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EDE28, NCT00334139
9.	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Phase: Phase IV Type: Diagnostic, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446GDE22, NCT00391690
10.	Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Phase: Phase IV Type: Natural history/Epidemiology, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EAU22, NCT00434447
11.	Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EUS129, NCT00622505
12.	Stage I Multiple Myeloma Treatment Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: IFM-04-01, NCT00733538
13.	Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Phase: Phase IV Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: CZOL446ECN06T, NCT00762346
14.	Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Phase: Phase IV Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: CZOL446ECN07, NCT00765687
15.	Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EUS147, NCT01129336
16.	Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446GDE19, NCT00375752
17.	Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 to 75 Sponsor: Other Protocol IDs: CZOL446ECN05, NCT00524849
18.	Phase III Randomized Study of Zoledronate Versus Pamidronate in Patients With Cancer-Related Bone Lesions Due to Multiple Myeloma or Breast Cancer Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NOVARTIS-4244603010, UCLA-9911015
19.	Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDR0000067052, NOVARTIS-4244603011, NCT00003884
20.	Phase III Randomized Study of Zoledronate in Patients With Bone Metastases Secondary to Prostate Cancer (Summary Last Modified 12/1999) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NOVARTIS-4244603039
21.	Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 40 and over Sponsor: NCI, Other Protocol IDs: CDR0000068781, U10CA031946, CALGB-79809, NCI-P01-0184, NCT00022087
22.	Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CDR0000069274, U10CA021115, E-E1A00, E1A00, NCT00033332
23.	Phase III Randomized Study of Zoledronate for the Prevention of Bone Loss in Premenopausal Women Receiving Adjuvant Chemotherapy For Early Stage Breast Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Supportive care Status: Closed Age: 18 to 50 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CPMC-IRB-14069, NCI-G02-2127, NOVARTIS-CPMC-IRB-14069, NCT00049452
24.	Phase III Randomized Study of Neoadjuvant or Adjuvant Chemotherapy and/or Hormonal Therapy With Versus Without Zoledronate in Women With Stage II or III Breast Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: SHEFF-AZURE, EU-20315, ISRCTN79831382, BIG-1-04, NCT00072020
25.	Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000353209, CALGB-90202, ECOG-CALGB-90202, SWOG-CALGB-90202, CAN-NCIC-PRC2, NCT00079001